This permits similar ASCT2 protein expression in both androgen‐dependent (LNCaP) and androgen‐independent (PC‐3) prostate cancer cell lines, and facilitates sufficient glutamine for cell growth. The gene discussed is SLC1A5; the disease is prostate carcinoma.